Drug Hunter
Drug Hunter Inc. is a resource dedicated to distilling the science behind emerging drugs and technologies into an easy-to-read, simple-to-search reference. Founded in 2018, it aims to empower R&D innovators by providing insights, patent highlights, and structure searches to facilitate drug discovery and development. The company serves a global community of researchers, pharma, biotech, and academic institutions, fostering a community built on science, data, clarity, and collaboration.
Industries
Nr. of Employees
small (1-50)
Products
Annotated searchable patent tables
Curated tables of notable patent disclosures with annotations linking structural clues to translational relevance.
Molecule case studies and target briefs
Detailed write-ups on individual molecules, mechanisms, structural insights, and clinical context.
Resource library (cheat sheets, posters, synthesis guides)
Downloadable practical resources for drug discovery workflows (PK cheat sheets, synthesis guides, posters).
Large-molecule approvals overview
Aggregated review of novel large-molecule regulatory approvals with links to regulatory labels and development insights.
Annotated searchable patent tables
Curated tables of notable patent disclosures with annotations linking structural clues to translational relevance.
Molecule case studies and target briefs
Detailed write-ups on individual molecules, mechanisms, structural insights, and clinical context.
Resource library (cheat sheets, posters, synthesis guides)
Downloadable practical resources for drug discovery workflows (PK cheat sheets, synthesis guides, posters).
Large-molecule approvals overview
Aggregated review of novel large-molecule regulatory approvals with links to regulatory labels and development insights.
Services
Paid subscription providing access to extended case studies, annotated patent tables, slide decks and member-only downloads.
Web application for structure-based searching and molecule profile lookup with linked translational information.
Searchable patent tools and recent-disclosures database aggregating first disclosures and patent-derived structures.
Live and recorded short scientific talks, webinars and slide deck distribution focused on drug discovery topics.
Regular email newsletter summarizing new disclosures, patent highlights, and curated drug discovery content.
Regular article summaries of clinical trial updates, approvals, trial initiations, and program terminations for pipeline tracking.
Paid subscription providing access to extended case studies, annotated patent tables, slide decks and member-only downloads.
Web application for structure-based searching and molecule profile lookup with linked translational information.
Searchable patent tools and recent-disclosures database aggregating first disclosures and patent-derived structures.
Live and recorded short scientific talks, webinars and slide deck distribution focused on drug discovery topics.
Regular email newsletter summarizing new disclosures, patent highlights, and curated drug discovery content.
Regular article summaries of clinical trial updates, approvals, trial initiations, and program terminations for pipeline tracking.
Expertise Areas
- Medicinal chemistry and small-molecule drug discovery
- Patent landscaping and patent annotation for discovery and IP monitoring
- Clinical pipeline monitoring and approval tracking
- Physics-based ADME/PK and CNS exposure prediction
Key Technologies
- Chemical-structure search and substructure/query search
- Patent text mining and annotation
- Searchable molecule and disclosures databases
- Physics-based ADME/PK modeling (E-sol and related metrics)
News & Updates
Building on our review of the 2024 novel small molecule drug approvals, we now shift focus to the 19 large molecule approvals, which account for 38% of the year's total. This group includes biologics, monoclonal antibodies, bispecific T-cell engagers, synthetic hormones, and oligonucleotides with standout achievements: 11 (58%) earned first-in-class designations, and nine (42%) earned Breakthrough Therapy status. In this article, you'll find a detailed overview of these large molecule approvals, including links to FDA labels and insights into their discovery and development journeys.
In April, Novartis’ atrasentan received accelerated approval from the FDA for IgAN, and two oral GLP-1 receptor agonists got ready to seek approval. Also in the last month, a potential first-in-class POLγ activator, a RAS-PI3Kα inhibitor, and an IRAK4 degrader started clinical trials. Meanwhile, Roche reported the first clinical data for a WRN inhibitor, and a potential first-in-class ATR inhibitor showed promise against solid tumors. But not all of the updates were positive: an anti-amyloid drug failed a Ph. III trial and a small molecule TNFαR1 inhibitor failed a Ph. II psoriasis trial.
In April, we followed several notable business developments in the drug discovery space: Nurix licensed a transcription factor degrader to Sanofi; Prazer Therapeutics raised $20M to advance its targeted protein degrader pipeline; and Merck KGaA announced a $3.9B acquisition of SpringWorks Therapeutics. Read more about these biopharma deals.
One of the key challenges in CNS projects is achieving sufficient unbound brain exposure to engage the target. Schrödinger's team has discovered the energy of solvation (E-sol) metric, which accurately predicts Kp,uu and has been validated with CNS-penetrant DLK inhibitors. Explore more in this detailed Drug Hunter article.
Building on our review of the 2024 novel small molecule drug approvals, we now shift focus to the 19 large molecule approvals, which account for 38% of the year's total. This group includes biologics, monoclonal antibodies, bispecific T-cell engagers, synthetic hormones, and oligonucleotides with standout achievements: 11 (58%) earned first-in-class designations, and nine (42%) earned Breakthrough Therapy status. In this article, you'll find a detailed overview of these large molecule approvals, including links to FDA labels and insights into their discovery and development journeys.
In April, Novartis’ atrasentan received accelerated approval from the FDA for IgAN, and two oral GLP-1 receptor agonists got ready to seek approval. Also in the last month, a potential first-in-class POLγ activator, a RAS-PI3Kα inhibitor, and an IRAK4 degrader started clinical trials. Meanwhile, Roche reported the first clinical data for a WRN inhibitor, and a potential first-in-class ATR inhibitor showed promise against solid tumors. But not all of the updates were positive: an anti-amyloid drug failed a Ph. III trial and a small molecule TNFαR1 inhibitor failed a Ph. II psoriasis trial.
In April, we followed several notable business developments in the drug discovery space: Nurix licensed a transcription factor degrader to Sanofi; Prazer Therapeutics raised $20M to advance its targeted protein degrader pipeline; and Merck KGaA announced a $3.9B acquisition of SpringWorks Therapeutics. Read more about these biopharma deals.
One of the key challenges in CNS projects is achieving sufficient unbound brain exposure to engage the target. Schrödinger's team has discovered the energy of solvation (E-sol) metric, which accurately predicts Kp,uu and has been validated with CNS-penetrant DLK inhibitors. Explore more in this detailed Drug Hunter article.